F
Fennec Pharmaceuticals Inc
NASDAQ:FENC
Fennec Pharmaceuticals Inc
NASDAQ:FENC
Price:
9.09 USD
-1.52%
Updated:
May 7, 2024
Fennec Pharmaceuticals Inc
Net Income (Common)
|
Fennec Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
F
|
Fennec Pharmaceuticals Inc
NASDAQ:FENC
|
Net Income (Common)
-$16m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$484m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is Fennec Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-16m
USD
-16m
USD
Based on the financial report for Dec 31, 2023, Fennec Pharmaceuticals Inc's Net Income (Common) amounts to -16m USD.
What is Fennec Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-10%
-10%
Over the last year, the Net Income (Common) growth was 32%. The average annual Net Income (Common) growth rates for Fennec Pharmaceuticals Inc have been 4% over the past three years , -10% over the past five years .
You don't have any saved screeners yet
